PTC Therapeutics Announces Additional Study Of Ataluren In Patients With Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Links shared publicly online about this topic.
- 1,442total visits
PTC Therapeutics Announces Additional Study Of Ataluren In Patients With Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
PTC Therapeutics, Inc. (PTC) announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmD
View full resource at medicalnewstoday.com
Tags: Genetic, Muscular Dystrophy, Clinical Trial, Men's Health
Most Recently Shared on January 20, 2010 at 6:12 pm By:
PTC Therapeutics Announces Additional Study Of Ataluren In Patients With Advanced Nonsense Mutation Duchenne/Becker Mu... http://mnt.to/3wwZ
Advertisement
